β肾上腺素能拮抗剂中毒的体外治疗:EXTRIP工作组系统综述与推荐
EXTRIP工作组通过系统综述纳入76项研究(含体外研究、动物实验、药代动力学研究及病例报告),评估体外治疗对β肾上腺素能拮抗剂(BAAs)中毒的效果。药代动力学数据显示阿替洛尔、纳多洛尔、普拉洛尔和索他洛尔可透析,而普萘洛尔等不可透析。仅37例中毒患者有临床数据,无法与历史对照进行可靠比较。工作组强推荐反对对普萘洛尔严重中毒使用体外治疗,对阿替洛尔或索他洛尔严重中毒未给出推荐,但肾功能受损时建议体外治疗,指征包括难治性心动过缓和低血压(阿替洛尔或索他洛尔)及反复尖端扭转型室速(索他洛尔)。
要点
- EXTRIP工作组强推荐反对对普萘洛尔严重中毒患者使用体外治疗(强推荐,极低质量证据)。
- 对阿替洛尔或索他洛尔严重中毒患者,工作组未给出体外治疗推荐,除非合并肾功能受损,此时建议体外治疗(弱推荐,极低质量证据)。
- 肾功能受损患者体外治疗指征:阿替洛尔或索他洛尔中毒所致难治性心动过缓和低血压,以及索他洛尔中毒所致反复尖端扭转型室速。
- 间歇性血液透析可透析阿替洛尔、纳多洛尔、普拉洛尔和索他洛尔;中度可透析醋丁洛尔、比索洛尔和美替洛尔;轻度可透析美托洛尔和他林洛尔;不可透析倍他洛尔、卡维地洛、拉贝洛尔、美吲洛尔、普萘洛尔和噻吗洛尔。
- 仅37例BAAs中毒患者有临床数据,无法对体外治疗与标准治疗的历史对照进行可靠比较。
适用人群与场景
- β肾上腺素能拮抗剂(BAAs)中毒患者。
- 严重普萘洛尔中毒患者。
- 严重阿替洛尔或索他洛尔中毒患者,尤其是合并肾功能受损者。
诊断标准与关键阈值
- 间歇性血液透析可透析性评估:阿替洛尔、纳多洛尔、普拉洛尔和索他洛尔为可透析;醋丁洛尔、比索洛尔和美替洛尔为中度可透析;美托洛尔和他林洛尔为轻度可透析;倍他洛尔、卡维地洛、拉贝洛尔、美吲洛尔、普萘洛尔和噻吗洛尔为不可透析。
处置流程与药物剂量
- EXTRIP工作组推荐反对对严重普萘洛尔中毒患者使用体外治疗(强推荐,极低质量证据)。
- 对严重阿替洛尔或索他洛尔中毒患者,工作组未给出体外治疗推荐(因风险与获益似乎平衡),除非合并肾功能受损,此时建议体外治疗(弱推荐,极低质量证据)。
- 肾功能受损患者体外治疗指征:阿替洛尔或索他洛尔中毒所致难治性心动过缓和低血压,以及索他洛尔中毒所致反复尖端扭转型室速。
- 其他BAAs虽被视为可透析,但临床数据有限,不足以制定推荐。
红旗征与不能漏的情况
- 阿替洛尔或索他洛尔中毒患者出现难治性心动过缓和低血压。
- 索他洛尔中毒患者出现反复尖端扭转型室速。
研究设计与关键结果
- 共纳入76项研究(4项体外研究、2项动物实验、1项药代动力学模拟研究、37项终末期肾病患者药代动力学研究、32项病例报告或病例系列)。
- 可获得334例患者的毒代动力学或药代动力学数据(包括阿替洛尔73例、普萘洛尔54例、索他洛尔17例)。
- 仅37例BAAs中毒患者有临床数据可供分析(包括阿替洛尔9例、普萘洛尔9例、索他洛尔9例),无法对体外治疗队列与仅接受标准治疗的历史对照进行可靠比较。
证据类型、等级与局限
- 证据类型:EXTRIP工作组系统综述与推荐(指南)。
- 推荐强度:强推荐(反对普萘洛尔使用体外治疗),弱推荐(肾功能受损时阿替洛尔或索他洛尔使用体外治疗)。
- 证据质量:极低质量证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对严重普萘洛尔中毒患者,不应使用体外治疗(强推荐,极低质量证据)。
- 对严重阿替洛尔或索他洛尔中毒患者,若合并肾功能受损且出现难治性心动过缓和低血压(阿替洛尔或索他洛尔)或反复尖端扭转型室速(索他洛尔),建议使用体外治疗(弱推荐,极低质量证据)。
- 其他BAAs的体外治疗因临床数据有限,不足以制定推荐。
指南或共识出处
- EXTRIP工作组系统综述与推荐,发表于Crit Care。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: β-adrenergic antagonists (BAAs) are used to treat cardiovascular disease such as ischemic heart disease, congestive heart failure, dysrhythmias, and hypertension. Poisoning from BAAs can lead to severe morbidity and mortality. We aimed to determine the utility of extracorporeal treatments (ECTRs) in BAAs poisoning.
METHODS: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.
RESULTS: A total of 76 studies (4 in vitro and 2 animal experiments, 1 pharmacokinetic simulation study, 37 pharmacokinetic studies on patients with end-stage kidney disease, and 32 case reports or case series) met inclusion criteria. Toxicokinetic or pharmacokinetic data were available on 334 patients (including 73 for atenolol, 54 for propranolol, and 17 for sotalol). For intermittent hemodialysis, atenolol, nadolol, practolol, and sotalol were assessed as dialyzable; acebutolol, bisoprolol, and metipranolol were assessed as moderately dialyzable; metoprolol and talinolol were considered slightly dialyzable; and betaxolol, carvedilol, labetalol, mepindolol, propranolol, and timolol were considered not dialyzable. Data were available for clinical analysis on 37 BAA poisoned patients (including 9 patients for atenolol, 9 for propranolol, and 9 for sotalol), and no reliable comparison between the ECTR cohort and historical controls treated with standard care alone could be performed. The EXTRIP workgroup recommends against using ECTR for patients severely poisoned with propranolol (strong recommendation, very low quality evidence). The workgroup offered no recommendation for ECTR in patients severely poisoned with atenolol or sotalol because of apparent balance of risks and benefits, except for impaired kidney function in which ECTR is suggested (weak recommendation, very low quality of evidence). Indications for ECTR in patients with impaired kidney function include refractory bradycardia and hypotension for atenolol or sotalol poisoning, and recurrent torsade de pointes for sotalol. Although other BAAs were considered dialyzable, clinical data were too limited to develop recommendations.
CONCLUSIONS: BAAs have different properties affecting their removal by ECTR. The EXTRIP workgroup assessed propranolol as non-dialyzable. Atenolol and sotalol were assessed as dialyzable in patients with kidney impairment, and the workgroup suggests ECTR in patients severely poisoned with these drugs when aforementioned indications are present.
参考来源
- Bouchard J, Shepherd G, Hoffman RS, et al. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Crit Care. 2021. PMID: 34112223. doi:10.1186/s13054-021-03585-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。